Measuring bone density and structure after stem cell transplant for acute leukemia
Checks bone density and structure over time in adults with acute myeloid leukemia after transplant.
Plain-language title generated from the registry record
Registry title: Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry
Key facts
- Where
- Amiens, Caen, Lille, and Rouen, FranceSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05161026, who can take part
Where in France
- CHU AmiensAmiens, FranceNo longer taking part
- CHU CaenCaen, FranceNo longer taking part
- CHU LilleLille, FranceNo longer taking part
- CHU RouenRouen, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Caen
- Trial code
- NCT05161026
- Record updated
- 16 December 2021
- Original description
Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.Read full original descriptionShow less
Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry Coupled With FRAX / TBS in Allo-HSCT
Evaluation of variation of mineral density and bone microarchitecture after allogeneic HSCTs transplant in hematologic malignancies. Comparison with the general population.
Inclusion: Cytological diagnosis of acute myeloid leukemia (AML) with indication for a first-line allo-HSCTs transplant; Patient affiliated to the social security system; For women of childbearing age, use of reliable contraception throughout the study in accordance with the CPR of the drugs used; The patient must be able to comply with study visits and per protocol procedures; Patient who has been informed of the study and has signed his informed consent.
Exclusion: History of fracture of the femoral neck prior to the diagnosis of hematologic malignancies; Corticotherapy > 3 months at a dose > 7.5mg/day prior to the diagnosis of hematological disease; Hematologic malignancies other than AML; Primary or secondary osteoporosis known to the diagnosis of hematologic malignancies; Pathologies influencing bone metabolism: known inflammatory rheumatism (rheumatoid arthritis, ...), primary hyperparathyroidism, chronic renal failure (GFR < or = at 30ml / min / 1.73m2); History of neoplasia with bone involvement (sarcoma, multiple myeloma, metastasis...) and/or any solid cancer less than 5 years old; Person under guardianship or curatorship, or unable to understand the purpose of the study; Known bone involvement related to AML at diagnosis; Autograft or anterior allograft; Pregnant or lactating woman.